Biodel Inc (BIOD) 1.38 $BIOD
Biodel's (BIOD) CEO Errol De Souza on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 13, 5:25PM CST
BIOD: 1.38 (-0.14)
Hot Stock: Biodel, Shares Drop 7.9% (BIOD)
Comtex SmarTrend(R) - Fri Feb 13, 10:09AM CST
Biodel (NASDAQ:BIOD) is one of today's worst performing low-priced stocks, down 7.9% to $1.40 on 1.6x average daily volume. Biodel has traded 714,000 shares thus far today, vs. average volume of 450,000 shares per day. The stock has underperformed the Dow (-7.9% to the Dow's 0.3%) and underperformed the S&P 500 (-7.9% to the S&P's 0.2%) during today's trading.
BIOD: 1.38 (-0.14)
Biodel FQ1 results
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 8:48AM CST
BIOD: 1.38 (-0.14)
Pacira Resolves Promotion Issues Related to Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:06PM CST
Pacira Pharmaceuticals Inc. (PCRX) announced that it has resolved its issue with the FDA related to the promotional aspects of its lead product Exparel.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14), PCRX: 113.94 (-0.91)
Biodel misses by $0.03
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 3:04PM CST
BIOD: 1.38 (-0.14)
Biodel Reports First Quarter Fiscal Year 2015 Financial Results
Marketwired - Thu Feb 12, 3:00PM CST
Biodel Inc. (NASDAQ: BIOD) today reported financial results for the first fiscal quarter ended December 31, 2014.
BIOD: 1.38 (-0.14)
UCB's Neupro Positive in Parkinson's Disease Study in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:58PM CST
UCB (UCBJF) announced positive top-line results from two phase III studies on Neupro for early- and advanced-stage Parkinson's disease in Chinese patients.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
McKesson Beats on Earnings & Revenues in Q3, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:32AM CST
McKesson Corporation (MCK) reported third-quarter fiscal 2015 (ended Dec 31, 2014) earnings of $2.89 per share, which comfortably beat the Zacks Consensus Estimate of $2.62.
ABC: 100.34 (+0.51), MCK: 224.89 (+0.12), CAH: 86.08 (+0.04), BIOD: 1.38 (-0.14)
Roche Reports Positive Data on Leukemia Drug Gazyva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 5:27PM CST
Roche Holding AG (RHHBY) announced positive results from a phase III study, GADOLIN, on leukemia drug Gazyva for indolent non-Hodgkin's lymphoma.
AGN: 229.49 (+1.87), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
BioSpecifics Announces Label Expansion for Xiaflex in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 2:31PM CST
Positive news flowed in for BioSpecifics Technologies Corp. (BSTC) when Swedish Orphan Biovitrum AB received approval from the European Commission to market Xiapex for an additional indication.
ENDP: 84.01 (+1.12), BSTC: 38.14 (-0.85), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Biodel to Report First Quarter Fiscal Year 2015 Financial Results on February 12, 2015
Marketwired - Thu Feb 05, 7:04AM CST
Biodel Inc. (NASDAQ: BIOD) will issue its first quarter fiscal year 2015 financial results on February 12, 2015. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
BIOD: 1.38 (-0.14)
Merck KGaA, Precision Biologics to Develop Cancer Antibody - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:46PM CST
Merck KGaA's (MKGAF) Life Science business, Merck Millipore announced an agreement with Texas-based Precision Biologics, Inc. for providing upstream process development services to the company for the advancement of a preclinical monoclonal antibody, NEO-201.
BCRX: 10.06 (-0.09), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Novartis' Alcon Receives FDA Approval for Pazeo Solution - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:07PM CST
Novartis A.G. (NVS) recently announced that its ophthalmology unit Alcon has received FDA approval for the ophthalmic solution Pazeo (olopatadine hydrochloride solution) 0.7% for the treatment of ocular itching associated with allergic conjunctivitis.
AGN: 229.49 (+1.87), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14), NVS: 102.20 (-0.17)
Salix Pharmaceuticals (SLXP) in Focus: Stock Jumps 5.1% - Tale of the Tape
Zacks Research Stuff - Zacks Investment Research - Wed Feb 04, 8:21AM CST
Salix Pharmaceuticals Ltd. (SLXP) was a big mover last session, as the company saw its shares rise over 5% on the day.
SLXP: 152.35 (+3.17), BIOD: 1.38 (-0.14)
Will McKesson (MCK) Disappoint Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 2:45PM CST
McKesson Corporation (MCK), a leading health care services provider, is scheduled to report its third-quarter fiscal 2015 results (ended Dec 31, 2014) on Feb 5.
ACT: 285.37 (+3.71), MCK: 224.89 (+0.12), BIOD: 1.38 (-0.14), RAD: 8.34 (+0.25)
Mallinckrodt Beats on Q1 Earnings, Sales Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 10:03AM CST
Mallinckrodt plc (MNK) reported adjusted earnings of $1.84 per share in the first quarter of fiscal 2015 (ended Dec 26, 2014), beating the Zacks Consensus Estimate of $1.57.
IPXL: 39.51 (+0.69), MNK: 115.01 (+2.51), ACT: 285.37 (+3.71), BIOD: 1.38 (-0.14)
Will Mallinckrodt (MNK) Disappoint Q1 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 4:50PM CST
Our proven model does not conclusively show that Mallinckrodt is likely to beat earnings this quarter.
MNK: 115.01 (+2.51), JNJ: 99.62 (+1.18), ACT: 285.37 (+3.71), BIOD: 1.38 (-0.14)
Shire's Vyvanse Label Expanded for Binge-Eating Disorder - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 2:45PM CST
Shire's (SHPG) Vyvanse gets further FDA approval; adds binge eating disorder to its label.
SHPG: 239.82 (+6.11), PETX: 16.52 (-0.10), NPSP: 45.88 (+0.03), BIOD: 1.38 (-0.14)
Biodel's (BIOD) CEO Errol De Souza on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 13, 5:25PM CST
BIOD: 1.38 (-0.14)
Hot Stock: Biodel, Shares Drop 7.9% (BIOD)
Comtex SmarTrend(R) - Fri Feb 13, 10:09AM CST
Biodel (NASDAQ:BIOD) is one of today's worst performing low-priced stocks, down 7.9% to $1.40 on 1.6x average daily volume. Biodel has traded 714,000 shares thus far today, vs. average volume of 450,000 shares per day. The stock has underperformed the Dow (-7.9% to the Dow's 0.3%) and underperformed the S&P 500 (-7.9% to the S&P's 0.2%) during today's trading.
BIOD: 1.38 (-0.14)
Biodel FQ1 results
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 8:48AM CST
BIOD: 1.38 (-0.14)
Pacira Resolves Promotion Issues Related to Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:06PM CST
Pacira Pharmaceuticals Inc. (PCRX) announced that it has resolved its issue with the FDA related to the promotional aspects of its lead product Exparel.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14), PCRX: 113.94 (-0.91)
Biodel misses by $0.03
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 3:04PM CST
BIOD: 1.38 (-0.14)
Biodel Reports First Quarter Fiscal Year 2015 Financial Results
Marketwired - Thu Feb 12, 3:00PM CST
Biodel Inc. (NASDAQ: BIOD) today reported financial results for the first fiscal quarter ended December 31, 2014.
BIOD: 1.38 (-0.14)
UCB's Neupro Positive in Parkinson's Disease Study in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:58PM CST
UCB (UCBJF) announced positive top-line results from two phase III studies on Neupro for early- and advanced-stage Parkinson's disease in Chinese patients.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
McKesson Beats on Earnings & Revenues in Q3, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:32AM CST
McKesson Corporation (MCK) reported third-quarter fiscal 2015 (ended Dec 31, 2014) earnings of $2.89 per share, which comfortably beat the Zacks Consensus Estimate of $2.62.
ABC: 100.34 (+0.51), MCK: 224.89 (+0.12), CAH: 86.08 (+0.04), BIOD: 1.38 (-0.14)
Roche Reports Positive Data on Leukemia Drug Gazyva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 5:27PM CST
Roche Holding AG (RHHBY) announced positive results from a phase III study, GADOLIN, on leukemia drug Gazyva for indolent non-Hodgkin's lymphoma.
AGN: 229.49 (+1.87), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
BioSpecifics Announces Label Expansion for Xiaflex in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 2:31PM CST
Positive news flowed in for BioSpecifics Technologies Corp. (BSTC) when Swedish Orphan Biovitrum AB received approval from the European Commission to market Xiapex for an additional indication.
ENDP: 84.01 (+1.12), BSTC: 38.14 (-0.85), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Biodel to Report First Quarter Fiscal Year 2015 Financial Results on February 12, 2015
Marketwired - Thu Feb 05, 7:04AM CST
Biodel Inc. (NASDAQ: BIOD) will issue its first quarter fiscal year 2015 financial results on February 12, 2015. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
BIOD: 1.38 (-0.14)
Merck KGaA, Precision Biologics to Develop Cancer Antibody - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:46PM CST
Merck KGaA's (MKGAF) Life Science business, Merck Millipore announced an agreement with Texas-based Precision Biologics, Inc. for providing upstream process development services to the company for the advancement of a preclinical monoclonal antibody, NEO-201.
BCRX: 10.06 (-0.09), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Novartis' Alcon Receives FDA Approval for Pazeo Solution - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:07PM CST
Novartis A.G. (NVS) recently announced that its ophthalmology unit Alcon has received FDA approval for the ophthalmic solution Pazeo (olopatadine hydrochloride solution) 0.7% for the treatment of ocular itching associated with allergic conjunctivitis.
AGN: 229.49 (+1.87), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14), NVS: 102.20 (-0.17)
Salix Pharmaceuticals (SLXP) in Focus: Stock Jumps 5.1% - Tale of the Tape
Zacks Research Stuff - Zacks Investment Research - Wed Feb 04, 8:21AM CST
Salix Pharmaceuticals Ltd. (SLXP) was a big mover last session, as the company saw its shares rise over 5% on the day.
SLXP: 152.35 (+3.17), BIOD: 1.38 (-0.14)
Will McKesson (MCK) Disappoint Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 2:45PM CST
McKesson Corporation (MCK), a leading health care services provider, is scheduled to report its third-quarter fiscal 2015 results (ended Dec 31, 2014) on Feb 5.
ACT: 285.37 (+3.71), MCK: 224.89 (+0.12), BIOD: 1.38 (-0.14), RAD: 8.34 (+0.25)
Mallinckrodt Beats on Q1 Earnings, Sales Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 10:03AM CST
Mallinckrodt plc (MNK) reported adjusted earnings of $1.84 per share in the first quarter of fiscal 2015 (ended Dec 26, 2014), beating the Zacks Consensus Estimate of $1.57.
IPXL: 39.51 (+0.69), MNK: 115.01 (+2.51), ACT: 285.37 (+3.71), BIOD: 1.38 (-0.14)
Will Mallinckrodt (MNK) Disappoint Q1 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 4:50PM CST
Our proven model does not conclusively show that Mallinckrodt is likely to beat earnings this quarter.
MNK: 115.01 (+2.51), JNJ: 99.62 (+1.18), ACT: 285.37 (+3.71), BIOD: 1.38 (-0.14)
Shire's Vyvanse Label Expanded for Binge-Eating Disorder - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 2:45PM CST
Shire's (SHPG) Vyvanse gets further FDA approval; adds binge eating disorder to its label.
SHPG: 239.82 (+6.11), PETX: 16.52 (-0.10), NPSP: 45.88 (+0.03), BIOD: 1.38 (-0.14)
